Additional Proxy Soliciting Materials (definitive) (defa14a)
21 Junho 2023 - 10:46AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a) of the
Securities
Exchange Act of 1934
Filed
by the Registrant ☒ Filed by a Party other than the Registrant ☐
☐ |
Preliminary
Proxy Statement |
|
|
☐ |
Confidential, for Use
of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
|
☐ |
Definitive Proxy Statement |
|
|
☒ |
Definitive Additional Materials |
|
|
☐ |
Soliciting Material under
§240.14a-12 |
Provectus
Biopharmaceuticals, Inc. |
(Name of registrant as
specified in its charter) |
|
|
(Name of person(s) filing
proxy statement, if other than the registrant) |
|
Payment of Filing Fee (Check
the appropriate box): |
☒ |
No
fee required |
|
|
☐ |
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11 |
|
(1) |
Title
of each class of securities to which transaction applies:
|
|
|
|
|
(2) |
Aggregate
number of securities to which transaction applies: |
|
|
|
|
|
|
|
(3) |
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined): |
|
|
|
|
|
|
|
(4) |
Proposed
maximum aggregate value of transaction: |
|
|
|
|
|
|
|
(5) |
Total
fee paid: |
|
|
|
|
|
|
☐ |
Fee paid previously
with preliminary materials. |
☐ |
Check box if
any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
|
|
|
|
(1) |
Amount
Previously Paid:
|
|
|
|
|
(2) |
Form,
Schedule or Registration Statement No.:
|
|
|
|
|
(3) |
Filing
Party: |
|
|
|
|
|
|
|
(4) |
Date
Filed: |
|
|
|
During
its annual meeting of stockholders to be held on June 21, 2023, Provectus Biopharmaceuticals, Inc. (the “Company”) will provide
an update about the Company’s clinical development, regulatory affairs, drug discovery work, manufacturing, intellectual property,
business development, and corporate development activities.
A
copy of the Company’s 2023 Annual Meeting of Stockholders presentation slides is attached.
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
Notícias em tempo-real sobre Provectus Biopharmaceuticals Inc (QB) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Provectus Biopharmaceuticals, Inc.